In March 2019, Natera and BGI China Genomics entered into a partnership to commercialize Natera’s Signatera test in China,1 and after two years of technology transfers and validation, the BGI/Natera Signatera Assay () is now officially available in the country. The assay can help facilitate innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions.